Dra. Anaïs Corma Gómez
Investigador Emergente
Grupo de Estudio de Riesgo Cardiometabólico y Renal
Presentación
Dr Anaïs Corma completed her specialization in Preventive Medicine and Public Health at the University Hospital of Granada. Since 2018, she has been engaged in clinical research while combining it with clinical healthcare activities. She joined the research group Clinical Virology and STIs, initially as part of a European project (HEPCARE, Grant Agreement 709844, European Commission, CHAFEA Agency), and later (May–December 2019) through a research intensification programme funded by the Carlos III Health Institute (ISCIII; I3SNS). In 2020, she was awarded a Río Hortega contract by ISCIII (CM19/00251). Additionally, she received a Clinical/Researcher contract through a competitive regional public call (ACTION B Clinical Researchers 2022-2026; B-0061-2021 Andalusian Health Service) and a Junior Postdoctoral contract (RH-0045-2021) also through a competitive regional public call. Besides, Dr Corma is a postdoctoral researcher in the CIBERINFEC group (CB21/13/00118).
Her research activity has focused on studying HIV infection, with a particular emphasis on associated liver and metabolic diseases, and viral hepatitis infections, addressing these topics from epidemiological, clinical, microbiological, molecular, and genetic perspectives. Her mainlines of research include: the natural history of HCV/HIV coinfection and the risk of clinical events after viral clearance; microelimination and prevention of HIV and HCV infections; and sexually transmitted infections (STIs) and emerging and re-emerging infections.
Dr Corma serve as Principal Investigator (PI) of the multicentre projects GEHEP-011 (SEIMC) and PI19/01312 (ISCIII), which focus on predictors of clinical events in patients with HCV achieving cure. Results from some of her work have been incorporated into major national clinical guidelines for managing liver disease in people living with HIV (GESIDA-SEIMC). She also leads the development of a predictive model for liver-related clinical events in patients with advanced liver damage after HCV cure (GLD21/00085, ISCIII-GILEAD). Through a regional competitive public call, she secured funding of €220,000 (ProyExcel_00944, PAIDI 2021 Excellence Projects, Ministry of Universities, Research, and Innovation, Andalusian Government) to develop predictive tools for mortality in patients with chronic HCV infection using AI-based approaches and – omic variables.
In the field of microelimination, she is the PI of the project GLD23/00122 (ISCIII-GILEAD), which aims to determine the prevalence of HCV infection among men who have sex with men attending sex-on-premises venues. She led one of the world’s largest cohorts of Mpox cases, involving over 20 centres across Spain. She has received numerous awards, including the prestigious Young Investigators Award from the National AIDS Study Group (GeSIDASEIMC). In 2021, she defended her doctoral thesis, earning the distinction of Outstanding Cum Laude and the Extraordinary Doctorate Award. She is a member of the Expert Committee for drafting the Second Andalusian Plan on HIV and other STIs (2022), a co-author of the national guidelines for Updated Recommendations on Pre-Exposure Prophylaxis for HIV Prevention in Spain (2022) by the AIDS Study Group (GESIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology, and a coauthor of the national guidelines for Managing Liver Disease in HIV Patients (2022), the Consensus Document on the Diagnosis and Treatment of Sexually Transmitted Infections in Adults, Children, and Adolescents (2023), and the Document on Post-Exposure Prophylaxis for HIV, HBV, and HCV (2024) by the same group. She is also a member of the Advisory Committee for the Andalusian Strategic Plan on Hepatitis and HIV, from the Andalusian Ministry of Health and Families (2021-2022). She has co-supervised three undergraduate theses (Faculty of Medicine of the University of Seville, 2021 and 2022) and is currently co-supervising two doctoral thesis. Additionally, she is a teaching collaborator in the Department of Medicine at the Faculty of Medicine of the University of Seville.
Most recently, Dr Corma secured a Juan Rodés contract (JR24/00044) at the Hospital Clínico Universitario de Valencia , where she is undertaking, among other tasks, the project ‘Development of a Predictive Model for Sexually Transmitted Infections in PrEP Users in Spain’ (PI24/00736), for which she
is the PI for which more than 10,000 PrEP users have been recruited so far.
